Stockscreener 앱 받기
12.18
2.44%
0.29
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal Pharmaceuticals, Inc. $AMRX Stock Position Lifted by Walleye Capital LLC - MarketBeat
Amneal’s Parkinson’s drug shows positive interim results By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals Inc Stock Analysis and ForecastFinancial Sector Performance & Outstanding Profit Strategies - earlytimes.in
Amneal Pharmaceuticals Reports 'Substantial Clinical Benefit' from Crexont in Phase 4 Study - marketscreener.com
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease - The Manila Times
Amneal (NASDAQ: AMRX) Phase 4 ELEVATE-PD shows CREXONT boosting ‘Good On’ time - Stock Titan
Will Amneal Pharmaceuticals Inc. stock deliver better than expected guidance2025 Growth vs Value & Weekly Market Pulse Updates - Newser
Amneal wins FDA approval for generic albuterol inhaler - World Aerosols
How Amneal Pharmaceuticals Inc. stock compares to market leaders2025 Top Gainers & Consistent Profit Alerts - Newser
How Back-to-Back RESTASIS and PROAIR Generics At Amneal Pharmaceuticals (AMRX) Has Changed Its Investment Story - Yahoo Finance
AT&T sues generic drugmakers over alleged price-fixing scheme - Reuters
FDA approves Amneal’s generic albuterol inhaler By Investing.com - Investing.com Canada
FDA Approval for Generic Restasis Might Change the Case for Investing in Amneal Pharmaceuticals (AMRX) - simplywall.st
Amneal receives FDA approval for Restasis generic - Eyes On Eyecare
FDA Approves Amneal Pharmaceuticals’ Albuterol Sulfate Inhalation Aerosol for Asthma and COPD Treatment - geneonline.com
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05% - Ophthalmology Times
Amneal Pharmaceuticals Receives US FDA Approval for Albuterol Sulfate Inhalation Aerosol - marketscreener.com
FDA approves Amneal’s generic albuterol inhaler - Investing.com
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol - The Manila Times
Amneal to Participate in Upcoming Investor Conferences - The Manila Times
Amneal (Nasdaq: AMRX) adds 2nd Q4 2025 inhaler with FDA approval in $1.5B market - Stock Titan
How institutional buying supports Amneal Pharmaceuticals Inc. stockWeekly Market Summary & Safe Entry Zone Identification - Newser
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% - Sahm
Amneal announces FDA approval of cyclosporine ophthalmic emulsion 0.05% - TipRanks
FDA approves Amneal’s generic Restasis for dry eye disease By Investing.com - Investing.com Australia
AbbVie (ABBV) Faces New Generic Competition for Restasis - GuruFocus
FDA approves Amneal’s generic Restasis for dry eye disease - Investing.com
Amneal Pharmaceuticals Wins FDA Approval for Generic Restasis, Plans Q1 Rollout - marketscreener.com
Amneal Pharmaceuticals Receives FDA Approval for Cyclosporine Ophthalmic Emulsion 0.05%, Expanding Its Leadership in Complex Ophthalmic Therapies - Quiver Quantitative
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25% - simplywall.st
Looking at the Narrative for Amneal as Analyst Targets Shift After Recent Milestones - Yahoo Finance
Is Amneal Pharmaceuticals Still an Opportunity After 61% Price Surge in 2025? - Yahoo Finance
Prudential Financial Inc. Sells 65,965 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $625,000 Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. $AMRX Holdings Lowered by Geode Capital Management LLC - MarketBeat
Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares? - sharewise.com
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick? - sharewise.com
Amneal gets FDA nod for Iohexol Injection - MSN
What insider trading reveals about Amneal Pharmaceuticals Inc. stockWeekly Trend Report & Smart Allocation Stock Tips - BỘ NỘI VỤ
Nomura Asset Management Co. Ltd. Buys New Shares in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Assessing Amneal Pharmaceuticals (AMRX) Valuation Following FDA Approval for Generic Omnipaque Launch in 2026 - Sahm
Amneal Pharmaceuticals stock hits 52-week high at $12.12 By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals stock hits 52-week high at $12.12 - Investing.com
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following FDA Approval of First Generic Omnipaque - Sahm
Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs - AOL.com
Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know - Finviz
Amneal gets U.S. FDA nod for Brekiya as a migraine treatment - MSN
Will Amneal Pharmaceuticals Inc. stock outperform Dow Jones index2025 Performance Recap & Stepwise Trade Execution Plans - newser.com
Amneal Pharmaceuticals (NASDAQ:AMRX) Director Sells $586,000.00 in Stock - MarketBeat
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks - Yahoo Finance
Ted Nark Sells 50,000 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Is Amneal Pharmaceuticals Inc. stock trading near support levelsTrade Volume Report & Low Risk Growth Stock Ideas - newser.com
Amneal Pharmaceuticals Insider Sold Shares Worth $586,000, According to a Recent SEC Filing - MarketScreener
[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
2.05%
0.35%
자본화:
|
볼륨(24시간):